Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Part of paid clinical trials in Aurora, Colorado.

Sponsor
Nurix Therapeutics, Inc.
Study ID
NCT07520006
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NX-5948 — DRUG
    Administered orally once daily as a capsule
  • venetoclax — DRUG
    Administered orally once daily as a tablet per prescribing information
  • rituximab — DRUG
    Administered as an intravenous (IV) infusion per prescribing information
  • obinutuzumab — DRUG
    Administered as an IV infusion per prescribing information

Study Details

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Key Dates

First listed
Apr 9, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
May 31, 2033
Completion
May 31, 2033

Study Design

Enrollment
150 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: NX-5948 + venetoclax
  • Experimental: NX-5948 + venetoclax + rituximab
  • Experimental: NX-5948 + venetoclax + obinutuzumab

Primary Outcome Measure

Number of participants with treatment-emergent adverse events [ Time Frame: Up to approximately 7 years ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Rocky Mountain Cancer CentersAuroraColorado80012-
University of MiamiCoral GablesFlorida33146-
Oncology Associates of OregonEugeneOregon97401-
UPMC Hillman Cancer CenterPittsburghPennsylvania15232-
SCRI Oncology PartnersNashvilleTennessee37203-
Texas Oncology - NortheastTylerTexas75702-

Find similar trials in Aurora, CO

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials
By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Rocky Mountain Cancer Centers· Aurora, COUniversity of Miami· Coral Gables, FLOncology Associates of Oregon· Eugene, ORUPMC Hillman Cancer Center· Pittsburgh, PASCRI Oncology Partners· Nashville, TNTexas Oncology - Northeast· Tyler, TX

Related Studies